Skip to Content

Hengan International Group Co Ltd - Stock Quote 01044

Rating as of

Morningstar's Hengan International Group Co Ltd Stock Analysis

Currency in HKD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Hengan: Rising Input Costs Exacerbate Challenges Amid Business Transition; Lowering FVE to HKD 49

Jacky Tsang Equity Analyst

Analyst Note

| Jacky Tsang |

No-moat Hengan reported 2021 results that missed our estimates across both the top line and margins. Continued disruptions in global logistics and rising commodities prices have dragged both sales and profits for the company. Progress in channel transition has been weaker than our expectations and was unable to reignite growth for the company. We lowered our 2022 estimates on revenue and profit margins due to continued headwinds in market competition and expectations for further cost pressure. We revise down our fair value estimates to HKD 49 per share from HKD 60 per share as a result, which implies 15 times 2022 P/E, 9 times EV/EBITDA, and 6% FCF yield. We think the near-term share price lacks catalysts and would be weighed on by low visibility in earnings.

Read Full Analysis

Hengan International Group Co Ltd's Company Profile

Business Description

Founded in 1985, Hengan International is a leading health and hygiene product manufacturer in China. Its business comprises tissue paper products (47% of sales), sanitary napkins (34% of sales), disposable diapers (11% of sales), and others.

Hengan Industrial City, Anhai Town
Jinjiang, 362261, China, People's Republic of
T +86 59585708888
Sector Consumer Defensive
Industry Household & Personal Products
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Stock Type
Employees 23,000